Impact of shorter duration of treatment on virological response rate in genotype 2 or 3 chronic hepatitis C virus infection

Indian Journal of Gastroenterology

Volumn 26, Issue 5, 2007, Pages 209-213

  Elefsiniotis, Ioannis S ^a,b,e   Pantazis, Konstantinos D ^b   Dimitroulopoulos, Dimitrios ^c   Koutsounas, Sotirios ^d   Moulakakis, Antonios ^a   Paraskevas, Emmanouel ^c  

^a HIPPOKRATION HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c 'Agios Savvas' Hospital   (Greece)

^d IKA Hospital   (Greece)

^e NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ABDOMINAL ULTRASOUND; ADULT; AGED; ARTICLE; BIOCHEMISTRY; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENOTYPE; GENOTYPE 2; GENOTYPE 3; HEMATOLOGY; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; SEROLOGY; SHORT COURSE THERAPY; SUSTAINED VIROLOGICAL RESPONSE; ULTRASOUND; VIRUS INFECTION; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 39049093709     PISSN: 02548860     EISSN: 02548860     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
2. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, et al. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-12.
3. National Institutes of Health. NIH Consensus Development Conference Statement: Management of Hepatitis C 2002, June 10-12, 2002. Bethesda, MD. NIH Consensus Development Program; 2002:19:1-46.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. PEGASYS International Study Group. Peginterferon a-2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004;140:346-55.
5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358;958-65.
6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
7. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al. Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
8. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9.
9. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-9.
10. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alpha-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
11. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon alpha-2a (40 KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7.
12. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2005;40:1260-5.
13. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
14. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
15. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virological response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52.
16. Manns MP. Adherence to combination therapy: influence on sustained virological response and economic impact. Gastroenterol Clin North Am 2004;33(Suppl 1):S11-S24.
17. Schiffman M, Pappas SC, Nyberg L, Greenbloom S, Gibas A, Bacons B, et al. Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 or 3. Final results of the ACCELERATE trial. J Hepatol 2006;44:S271.